Department of Internal Medicine, Rheumatology and Clinical Immunology, Faculty in Katowice, Medical University of Silesia, 40-635 Katowice, Poland.
Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.
Int J Mol Sci. 2020 Oct 7;21(19):7390. doi: 10.3390/ijms21197390.
Janus kinase (JAK) inhibitors, a novel class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs), have shown their safety and efficacy in rheumatoid arthritis (RA) and are being intensively tested in other autoimmune and inflammatory disorders. Targeting several cytokines with a single small compound leads to blocking the physiological response of hundreds of genes, thereby providing the background to stabilize the immune response. Unfortunately, blocking many cytokines with a single drug may also bring some negative consequences. In this review, we focused on the activity of JAK inhibitors in the cardiovascular system of patients with RA. Special emphasis was put on the modification of heart performance, progression of atherosclerosis, lipid profile disturbance, and risk of thromboembolic complications. We also discussed potential pathophysiological mechanisms that may be responsible for such JAK inhibitor-associated side effects.
Janus 激酶（JAK）抑制剂是一类新型的靶向合成的治疗风湿性疾病的药物（DMARDs），已在类风湿关节炎（RA）中显示出其安全性和有效性，并正在其他自身免疫性和炎症性疾病中进行深入测试。用单一小分子化合物针对几种细胞因子，可阻断数百个基因的生理反应，从而为稳定免疫反应提供基础。不幸的是，用单一药物阻断许多细胞因子也可能带来一些负面后果。在这篇综述中，我们重点关注 JAK 抑制剂在 RA 患者心血管系统中的活性。特别强调了对心脏功能、动脉粥样硬化进展、血脂谱紊乱和血栓栓塞并发症风险的影响。我们还讨论了可能导致这种 JAK 抑制剂相关副作用的潜在病理生理机制。
